drug

Tryptophan

MeSH D014364
as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by University of Maryland, Baltimore County
2 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Trials

2
The Effects of Kynurenine Aminotransferase Inhibition in People With Schizophrenia
NCT04013555Phase 1, Phase 2Completed
Tryptophan MRI in People With Schizophrenia and Healthy Controls
NCT02067975Phase 2, Phase 3Completed

KOLs & investigators

1
Robert C Smith, M.D., Ph.DKOL score 5

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
University of Maryland, Baltimore County
company
trial
The Effects of Kynurenine Aminotransferase Inhibition in People With Schizophrenia
PHASE1, PHASE2
trial
Tryptophan MRI in People With Schizophrenia and Healthy Controls
PHASE2, PHASE3
trial
indication
Schizophrenia
indication
Schizophreniform Disorder
indication
Schizophrenia
indication
Psychotic Disorders
indication
KOL
Robert C Smith, M.D., Ph.D
KOL score 5
person